




## Company Profile

AION Diagnostics is a global research-based imaging company with a vision to enhance the delivery of care through early detection and diagnosis of disease. AION is committed to commercialization of contrast and molecular imaging agents, allowing timely intervention before symptoms arise.

Based on a novel discovery made by QinetiQ, formerly the UK Government Defense Evaluation & Research Agency (DERA), porous silicon is biodegradable and biocompatible in animals and humans. AION has created a unique imaging portfolio of products based on a modified form of porous silicon (mpSi), providing a unique ability for visualization on all key imaging modalities in a single formulation.

AION has secured operating facilities and expertise in the US, Europe and Australia.




### Product Development

AION has three product divisions; Marking Agents, Hybrid Contrast Agents and Molecular Imaging Agents. The technology offers significant opportunity for incorporation into other surgically implanted products for post-operative localization and monitoring.

### Platform Technology

mpSi retains key properties of silicon and is specifically engineered and stabilized for *in-vivo* hybrid imaging. mpSi can be engineered to remain in-situ or degrade at a controlled rate. mpSi's unique properties results in biodegradation in the body into silicic acid, a naturally occurring, non toxic and essential element that is excreted by the kidneys.



### Product Portfolio

- **Marking Agent**  
Marking Agents are used in a variety of surgical procedures to mark a site of interest for future relocation, monitoring and/or therapy. Combinations of materials currently achieve visibility on several modalities. The Marking Agent, based on the mpSi platform, provides significant advantage through controlled biodegradation, flexibility in size and design, and ease-of-use through conformance with a variety of application techniques. The Marker is uniquely versatile allowing incorporation into other surgical devices for visualization across all key imaging modalities and is regulated as a device for registration filing.
- **Hybrid Contrast Agent**  
Visible on all key imaging modalities using a single formulation, AION's Contrast Agent provides significant advantages over traditional imaging agents. The rate of degradation can be adjusted to suit the procedure, offering an agent that can be altered to last minutes, or hours, depending on the requirements. Silicic acid, the product of mpSi degradation, occurs naturally in human tissue and sera.
- **Molecular Imaging Applications**  
Molecular imaging provides the means to look at the surface or inside the cell to identify and visualize defects that may have been caused by a disease or clinical condition. Current challenges in molecular imaging include the limitation to "see" sufficient targeted cells inside tiny areas of tissue. AION's solution is a nano-scale product visible in clinical settings, offering the potential to provide real-time signals of early disease development.

### Intellectual Property

AION owns exclusive intellectual property rights for the use of porous silicon in the body for imaging purposes, with additional patent applications in the imaging sector. AION's IP Portfolio covers 14 Patent Families, 21 Granted Patents, 45 Patent Applications in key markets including US, Europe and Australia.



## Board of Directors



**Dr. Jörg Schreiber** - Chairman

Dr. Jörg Schreiber has over 20 years experience in the diagnostic industry, whilst working with a global leader in the sector. Jörg joined Boehringer Mannheim in 1986, which became Roche Diagnostics. During his time at Roche, he held key senior roles including Vice President for R&D and Special Projects in the US. Dr. Schreiber holds a Ph.D. in physics from Giessen University, Germany, and also holds several board positions in professional, civic and art organizations, where he works in an interdisciplinary context.



**Dr. Anna Kluczevska** - President / CEO

Dr. Kluczevska is a highly qualified clinician with former global product management experience at Baxter Healthcare's BioSurgery Division. Anna oversaw product management in over 50 countries. Start up company experience includes general and operations management, intellectual property development, capital raising and investor relations, and continuing executive management of seed project through to cash-flow-positive publicly listed company. Dr. Kluczevska is also a Member of the Advisory Board to the Chemistry Centre of Western Australia.



**Prof. Leigh Canham** - Director and Chief Scientific Officer

Professor Leigh Canham has spent the past twenty years conducting research on differing aspects of silicon technology. He has made two seminal discoveries at the former UK Government Defense Evaluation and Research Agency (DERA - now QinetiQ); that nanostructured silicon can emit light efficiently (1990); and that silicon can be rendered biodegradable (1995). Professor Canham is the world's foremost authority on porous silicon.



**Mr. Aaron Finlay** - Chief Financial Officer and Company Secretary

Mr. Aaron Finlay's most recent role was as INVESCO Australia's Chief Financial Officer. In this role, Aaron had responsibility for the operations of finance, compliance, legal and human resources functions. Prior to this Mr. Finlay was based in INVESCO's head offices in London where he was Head of Group Tax and Treasury for INVESCO's global operations.

**Forward-looking statements** - As regards forecasts, estimates, opinions or expectations expressed or forward-looking statements made in the following information, such expressions and statements may involve known and unknown risks and uncertainties. Future results and developments may therefore differ substantially from such expectations and assumptions expressed.

For more information, visit [www.aiondiagnostics.com](http://www.aiondiagnostics.com) or contact:

**Dr. Eva Reuter**  
European Public Relations  
Email: [e.reuter@dr-reuter.eu](mailto:e.reuter@dr-reuter.eu)  
Tel: +49 (254) 393 0740

**Alexandra Brown**  
AION Diagnostics  
Email: [alexandra\\_brown@aiondiagnostics.com](mailto:alexandra_brown@aiondiagnostics.com)  
Tel: +61 8 6461 9400